Black patients referred to a lung cancer screening program experience lower rates of screening and longer time to follow-up

Table 6 Adherence to Follow-Up Among Patients with a Positive Baseline Screen

Lung-RADS 3
	Black Patients n = 21	White Patients n = 22
Mean Age ± SD	65.1 ± 5.7	65.1 ± 5.0
Sex
• Female	11 (52.4%)	8 (36.4%)
• Male	10 (47.6%)	14 (63.6%)
Overall adherence^a, n (%)	19 (90.5%)	20 (90.9%)
Time to follow-up CT^b, mean mos ± SD	8.5 ± 4.5	6.6 ± 3.0
Timely adherence^c, n (%)	12 (63.2%)	16 (80.0%)
Screen-detected cancer	2 (9.1%)	0 (0%)
Patients eligible for screening or nodule surveillance	18^d	21^e
• Return to annual screening or nodule surveillance	11 (61.1%)	12 (57.1%)
• Lost to follow-up^f	7 (38.9%)	9 (42.9%)
Lung-RADS 4
	Black Patients n = 14	White Patients n = 13
Mean Age ± SD	688 ± 5.8	65.2 ± 4.3
Sex
• Female	5 (35.7%)	3 (23.1%)
• Male	9 (64.3%)	10 (76.9%)
Overall adherence^a, n (%)	14 (100%)	13 (100%)
Time to follow-up CT^b, mean mos ± SD	3.1 ± 2.9	2.1 ± 1.5
Timely adherence^c, n (%)	10 (71.4%)	10 (76.9%)
Screen-detected cancer	5 (35.7%)	3 (30.8%)
Patients eligible for screening or nodule surveillance	9	9
• Return to annual screening or nodule surveillance	3 (33.3%)	6 (66.7%)
• Lost to follow-up^f	6 (66.7%)	3 (33.3%)

^a Overall adherence was defined as any follow-up CT chest following the baseline LDCT
^b Time to follow-up was measured among screened patients who were adherent with any follow-up CT
^c On-time adherence was defined as a follow-up CT within 30 days of the recommended time-frame for follow-up (4 months for Lung-RADS 3 or 4)
^dOne black, Lung-RADS 3 patient became ineligible during the follow-up period due to smoking cessation > 15 years prior
^eOne white, Lung-RADS 3 patient died during the follow-up period
^f Lost to follow-up was defined by current status

ISSN: 1471-2407